Objective: Severe acute respiratory distress syndrome (ARDS) is often complicated by hemodynamic instability requiring pharmacological support. Venovenous extracorporeal membrane oxygenation (VV ECMO) is a well-established technique that contributes to improved outcomes in this population. However, the effects of VV ECMO on inotropic and vasoconstrictor requirements have never been addressed in a large case series. Design: Observational study. Setting: University hospital. Participants: Consecutive adult ARDS patients treated with VV ECMO. Measurements and Main Results: From June 2009 to October 2023, 118 ARDS patients received VV ECMO and had available baseline data. The median patient age was 57 years, 65% of patients were male, and 76% had ongoing inotropic and/or vasoconstrictor support. Two hours after ECMO implantation, 61% of patients showed hemodynamic improvement, as documented by the reduced need for catecholaminergic support or increased mean arterial pressure with identical inotropic and/or vasoconstrictor support. This percentage increased to 63% at 12 hours, 83% at 24 hours, and 85% at 48 hours. Conclusion: In the first 2 hours after VV ECMO implantation, hemodynamic improvement was observed in the majority of ARDS patients. This positive effect might therefore be considered in the decision-making process for VV ECMO implantation.
Objective: Severe acute respiratory distress syndrome (ARDS) is often complicated by hemodynamic instability requiring pharmacological support. Venovenous extracorporeal membrane oxygenation (VV ECMO) is a well-established technique that contributes to improved outcomes in this population. However, the effects of VV ECMO on inotropic and vasoconstrictor requirements have never been addressed in a large case series. Design: Observational study. Setting: University hospital. Participants: Consecutive adult ARDS patients treated with VV ECMO. Measurements and Main Results: From June 2009 to October 2023, 118 ARDS patients received VV ECMO and had available baseline data. The median patient age was 57 years, 65% of patients were male, and 76% had ongoing inotropic and/or vasoconstrictor support. Two hours after ECMO implantation, 61% of patients showed hemodynamic improvement, as documented by the reduced need for catecholaminergic support or increased mean arterial pressure with identical inotropic and/or vasoconstrictor support. This percentage increased to 63% at 12 hours, 83% at 24 hours, and 85% at 48 hours. Conclusion: In the first 2 hours after VV ECMO implantation, hemodynamic improvement was observed in the majority of ARDS patients. This positive effect might therefore be considered in the decision-making process for VV ECMO implantation.
Hemodynamic Improvement in Acute Respiratory Distress Syndrome Patients After Venovenous Extracorporeal Membrane Oxygenation Implantation / Labanca, Rosa; Pieri, Marina; Monti, Giacomo; Fresilli, Stefano; Nardelli, Pasquale; Baldetti, Luca; Fominskiy, Evgeny; Zangrillo, Alberto; Landoni, Giovanni; Scandroglio, Anna Mara; Calabrò, Maria Grazia; Franco, Annalisa; Ortalda, Alessandro; Scquizzato, Tommaso; Fiorito, Sara; Lembo, Rosalba. - In: JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA. - ISSN 1053-0770. - 39:5(2025), pp. 1221-1228. [10.1053/j.jvca.2025.01.011]
Hemodynamic Improvement in Acute Respiratory Distress Syndrome Patients After Venovenous Extracorporeal Membrane Oxygenation Implantation
Labanca, RosaPrimo
;Pieri, Marina;Monti, Giacomo;Fresilli, Stefano;Nardelli, Pasquale;Zangrillo, Alberto;Landoni, Giovanni;Ortalda, Alessandro;Scquizzato, Tommaso;
2025-01-01
Abstract
Objective: Severe acute respiratory distress syndrome (ARDS) is often complicated by hemodynamic instability requiring pharmacological support. Venovenous extracorporeal membrane oxygenation (VV ECMO) is a well-established technique that contributes to improved outcomes in this population. However, the effects of VV ECMO on inotropic and vasoconstrictor requirements have never been addressed in a large case series. Design: Observational study. Setting: University hospital. Participants: Consecutive adult ARDS patients treated with VV ECMO. Measurements and Main Results: From June 2009 to October 2023, 118 ARDS patients received VV ECMO and had available baseline data. The median patient age was 57 years, 65% of patients were male, and 76% had ongoing inotropic and/or vasoconstrictor support. Two hours after ECMO implantation, 61% of patients showed hemodynamic improvement, as documented by the reduced need for catecholaminergic support or increased mean arterial pressure with identical inotropic and/or vasoconstrictor support. This percentage increased to 63% at 12 hours, 83% at 24 hours, and 85% at 48 hours. Conclusion: In the first 2 hours after VV ECMO implantation, hemodynamic improvement was observed in the majority of ARDS patients. This positive effect might therefore be considered in the decision-making process for VV ECMO implantation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


